Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register

Size: px
Start display at page:

Download "Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register"

Transcription

1 EUROPEAN JOURNAL OF CANCER 43 (2007) available at journal homepage: Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register Alessandro Marinaccio a, *, Alessandra Binazzi a, Gabriella Cauzillo b, Domenica Cavone c, Renata De Zotti d, Pierpaolo Ferrante a, Valerio Gennaro e, Giuseppe Gorini f, Massimo Menegozzo g, Carolina Mensi h, Enzo Merler i, Dario Mirabelli j, Fabio Montanaro e, Marina Musti c, Franco Pannelli k, Antonio Romanelli l, Alberto Scarselli a, Rosario Tumino m, Italian Mesothelioma Register (ReNaM) Working Group n a National Institute for Occupational Safety and Prevention (ISPESL), Occupational Medicine Department, Epidemiology Unit, Via Alessandria 220/E, Rome, Italy b Regional Operating Center of Basilicata (COR Basilicata), Epidemiologic Regional Center, Via Anzio, Potenza, Italy c COR Puglia, University of Bari, Department of Internal Medicine and Public Medicine, Section of Occupational Medicine B.Ramazzini, Piazza Giulio Cesare, Bari, Italy d COR Friuli-Venezia Giulia, University of Trieste, Occupational Medicine Unit, Via Pietà 19, Trieste, Italy e COR Liguria, Epidemiology and Prevention Department, National Cancer Research Institute (IST), Largo R. Benzi, 10, Genova, Italy f COR Tuscany, Center for Cancer Study and Prevention, Epidemiology Unit, Via di S. Salvi 12, Firenze, Italy g COR Campania, II University of Naples, Experimental Medicine Department, Piazza Miraglia 2, Napoli, Italy h COR Lombardy, Department of Occupational and Environmental Health, Fondazione IRCCS Policlinico, Mangiagalli, Regina Elena and University of Milan, Via San Barnaba 8, Milano, Italy i COR Veneto, Padova Health Local Unit, Via dell Ospedale 22, Padova, Italy j COR Piedmont, Unit of Cancer Prevention, University of Turin and S. Giovanni Battista Hospital, Via Santena 7, Torino, Italy k COR Marche, University of Camerino, Hygienistic, Environmental and Health Sciences Department, Via E. Betti 3, Camerino, Italy l COR Emilia-Romagna, Health Local Unit, Public Health Department, Via Amendola 2, Reggio Emilia, Italy m COR Sicily, Civile - M.P. Arezzo Hospital, Ragusa Cancer Register Unit, Via Dante 109, Ragusa, Italy ARTICLE INFO ABSTRACT Article history: Received 12 July 2007 Received in revised form 13 September 2007 Accepted 24 September 2007 Available online 5 November 2007 Keywords: Mesothelioma National register Italy was an important producer of raw asbestos until 1992 (when it was banned) and it is now experiencing severe public health consequences due to large-scale industrial use of asbestos in shipbuilding and repair, asbestos-cement production, railways, buildings, chemicals and many other industrial sectors. Latency of malignant mesothelioma generally shows a large variability and the relationship with the modality of asbestos exposure is still not fully clarified. We present an analysis of latency period among the case list collected by the Italian mesothelioma register (ReNaM) in the period of diagnosis (2544 malignant mesothelioma (MM) cases with asbestos exposure history). Exposure is assessed retrospectively by interview. Statistical univariate analyses were performed to estimate median and variability measures of latency time by anatomical site, gender * Corresponding author: Tel.: ; fax: address: alessandro.marinaccio@ispesl.it (A. Marinaccio). n ReNaM Working Group: Tosi S, Branchi C (ISPESL), Convertini L (COR Basilicata), Bianchelli M, Benfatto L, Lazzarotto A, Viarengo P (COR Liguria), Seniori-Costantini A, Badiali A, Cacciarini V, Chellini E, Silvestri S (COR Toscana), Menegozzo S, Izzo F (COR Campania), Riboldi L, Pesatori AC (COR Lombardia), Gioffrè F, Ballarin N, Roberti S (COR Veneto), Bertolotti M, Stura A, Gangemi M, Merletti F (COR Piemonte), Pascucci C (COR Marche), Candela S, Mangone L, Pezzarossi A, Storchi C (COR Emilia-Romagna), Scondotto S, Cianciolo G, Nicita C, Dardanoni G, Di Giorgi M, Miceli G, Mira A (COR Sicilia) /$ - see front matter Ó 2007 Elsevier Ltd. All rights reserved. doi: /j.ejca

2 EUROPEAN JOURNAL OF CANCER 43 (2007) Latency Asbestos exposure Italy and diagnosis period. The role of diagnostic confidence level, the morphology of the tumour and the modalities of asbestos exposure were verified in a regression multivariate model. We found a median latency period of 44.6 years increasing in recent years with a linear trend. Anatomical site, gender and morphology were not relevant for MM latency time whereas a shorter latency period was documented among occupationally exposed subjects (43 years) with respect to environmentally and household exposed ones (48 years). Ó 2007 Elsevier Ltd. All rights reserved. 1. Introduction 2. Methods Malignant mesothelioma (MM) is a lethal tumour which arises from the serosal coverings of the pleura and, less frequently, of the pericardial and peritoneal cavities and from the tunica vaginalis of the testis. The relationship with asbestos exposure has been definitely demonstrated, but some aspects of biological mechanisms by which asbestos causes MM are still under scrutiny. 1 Latency time for MM shows a great variability and the relationship with the asbestos exposure intensity (and duration) is still not clarified. The range of latency period in the published study is exceptionally extensive and MM cases with a latency period shorter than 10 years are very rare. Some authors reported that latency has increased during the time due to less heavy exposure conditions, 2 but this remains a controversial issue. 3 Data regarding the influence of dose-response on latency are not frequent and there is no evidence about the putative role of other factors such as tumour site, asbestos fibre types and morphology. 4 7 Italy was an important producer of raw asbestos until its ban in In-house production peaked at more than 160,000 tons/year between 1976 and 1979, then it went on with more than 100,000 tons/year up to 1987; additionally, importation exceeded in-house production from 1989 to 1991 (more than 60,000 tons/year). Italy is now experiencing severe public health consequences due to large-scale industrial use of asbestos, as it was extensively used in shipbuilding and repair, asbestos-cement production, railways, buildings, chemicals and other industrial sectors. In 2001, 797 men and 380 women deceased from pleural tumours and the national standardised mortality rate was 2.45 and 1.11 ( 100,000 inhabitants) among men and women respectively. Historical Italian asbestos consumption curves and current MM mortality trends make a decrease of MM deaths in future years unpredictable. 8,9 Since 1993, the National Mesothelioma Registry (ReNaM) has carried out a permanent MM epidemiologic surveillance, recently publishing figures for incidence, survival and asbestos exposure The aim of the present study is to estimate the latency period (and its variability) in the large MM case list collected by ReNaM. The correlation between latency length and the modalities of asbestos exposure (professional, environmental or at leisure) are investigated, as well as the putative influence on latency of demographic and diagnostic factors (age at diagnosis, gender, anatomical site, cancer morphology, level of diagnostic certainty and incidence period). ReNaM has a regional structure: a Regional Operating Centre (COR) has been progressively established in 18 Italian regions (out of 21) and one province, nowadays attaining coverage of almost the entire national territory (98.5% of the Italian population). Each COR acts independently applying standardised methods established by national guidelines. CORs collect incident malignant mesothelioma cases from health care institutions that diagnose and treat cases of mesothelioma (especially pathology and histology units, lung disease pneumology and chest surgery wards), and consult hospital discharge records and death certificates to verify for completeness of inclusion and information. Diagnostic criteria have been fixed by national guidelines and all cases of malignant mesothelioma are included and registered in ReNaM according to diagnostic certainty achieved (defined, probable, possible). Occupational history, lifestyle habits and residential hystory are obtained from the subject (48.3%) or next of kin (51.7%) using a standardised questionnaire administered by a trained interviewer. To obtain information on occupational and/or residential exposure, CORs consult local health and public hygiene offices, and regional occupational prevention, hygiene and safety agencies. An industrial hygienist classifies and codes the exposure, consulting the questionnaires and appling his own knowledge of industrial conditions. Occupational exposure was classified as definite, probable or possible. Definite occupational exposure is assigned to the subjects whose work has involved the use of asbestos or materials containing asbestos. Probable occupational exposure is assigned to the subjects who have worked in a firm or sector where asbestos was certainly used, but whose exposure cannot be documented, and possible occupational exposure to the subjects who have worked in a firm or sector where asbestos might have been used. 10 Data collected by each COR are then periodically transmitted to Renam and stored in a centralised database. During the period , 5173 mesothelioma incident cases have been registered among the inhabitants of 12 regions (out of the 20 Italian regions): Piedmont, Veneto, Puglia, Tuscany and Emilia-Romagna provided cases since the beginning of the period, Liguria since 1994, Friuli-Venezia Giulia between 1995 and 1999, Marches since 1996, Sicily since 1998, Lombardy, Campania and Basilicata since In Friuli-Venezia Giulia, Campania and Basilicata, incident cases active research could not be considered completed. Data collection and trasmission from the remaining eight Italian regions is ongoing.

3 2724 EUROPEAN JOURNAL OF CANCER 43 (2007) Latency time is here defined as the time elapsing between the beginning of asbestos exposure and MM diagnosis. For occupationally exposed subjects, the first year in the job activity involving asbestos exposure (certain, probable, possible) was considered the year of first exposure. For non-occupationally exposed cases, the whole residential and life habit history was evaluated to assess the first asbestos exposure among environmental, household and hobby-related ones. Information about exposure circumstances were not available for 1621 cases (questionnaires could not be administered, generally because of the poor health of the patients). Asbestos exposure was unlike or unknown (i.e. questionnaires reported an incomplete job and/or residential history) for 809 cases MM cases had (at least) an occupational and non-occupational asbestos exposure ascertained and were reliable, but 199 of them did not mention the year of first exposure, thus they were not considered. Finally, latency time analysis was conducted on the remaining 2544 patients: 2342 of them had experienced an occupational asbestos exposure and 202 exclusively a non-occupational exposure (household, environmental or hobbies-related). Univariate analysis was performed to estimate mean and median latency period by anatomical site and gender. Range of variation, standard deviation of the mean and 5th and 95th percentiles were calculated to assess the variability of latency distribution. Differences among mean latencies with respect to the year of diagnosis have been tested by one-way analysis of variance (ANOVA) at a statistical significance level of 95%. Test for linear trend in ANOVA has been performed with respect to the year of diagnosis. A multivariate analysis restricted to pleural and peritoneal mesothelioma (2537 cases) was conducted by way of a linear generalised regression model. Other anatomical sites (seven cases) were excluded so as not to reduce the degrees of freedom of the model. Region of notification has been found not relevant and excluded from the definitive model for the same reason. Diagnosis confidence level (definite; probable; possible MM), tumour morphology (fibrous; epithelioid; biphasic; not specified), asbestos exposure circumstances (professional; household; environmental; leisure), gender (male; female) and anatomical sites (pleura; peritoneum) were considered in the model as factors; age at diagnosis and year of diagnosis as covariates. To assess the significance of differences in latency time between occupationally and non-occupationally asbestos exposed MM cases, marginal mean adjusted for factors and covariates included in the model were estimated in the generalised model. All statistical analyses were performed using the Statistical Package for Social Sciences (SPSS version 15.0). 3. Results The ReNaM dataset included 5173 new MM cases diagnosed during the period Applying the selection criteria described above, 2544 patients (49.2%) came out to be eligible for latency analysis. The general characteristics of this cohort Table 1 Incident malignant mesothelioma cases with available first exposure to asbestos, recorded by ReNaM in the diagnosis period Variable Modality Males Females Anatomical site Pleura 2075 (95.8%) 360 (95%) Peritoneum 83 (3.8%) 19 (5%) Pericardium 2 (0.1%) Tunica vaginalis testis 5 (0.2%) Age classes (13.4%) 61 (16.1%) (28.8%) 110 (29%) (36%) 122 (32.2%) P (21.8%) 86 (22.7%) Diagnosis certainty MM certain 1804 (83.3%) 310 (81.8%) MM probable or possible 361 (16.7%) 69 (18.2%) Asbestos exposure Occupational 2091 (96.6%) 251 (66.2%) Household 14 (0.6%) 70 (18.5%) Environmental 51 (2.4%) 47 (12.4%) Hobbies related 9 (0.4%) 11 (2.9%) Morphology Epithelioid 1089 (50.3%) 228 (60.2%) Biphasic 267 (12.3%) 46 (12.1%) Fibrous 169 (7.8%) 30 (7.9%) Not specified 640 (29.6%) 75 (19.8%) Diagnosis period (31.7%) 94 (24.8%) (68.3%) 285 (75.2%) Year of starting asbestos exposure (49.9%) 198 (52.2%) > (50.1%) 181 (47.8%) Total Figures by gender, anatomical site, age at diagnosis, period of diagnosis, exposure modalities, morphology and year of first exposure.

4 EUROPEAN JOURNAL OF CANCER 43 (2007) Table 2 Incident malignant mesothelioma cases with available first exposure to asbestos, recorded by ReNaM in the diagnosis period Anatomical site Gender Number of cases Mean latency (±Standard deviation) Median latency Range of variation (min-max) 5 95 percentile Pleura Males (±11.9) Females (±13.6) Peritoneum Males (±9.9) Females (±10.2) Mean, median and variability measures of latency time by anatomical site (pleura and peritoneum) and gender. Table 3 Incident malignant mesothelioma cases with available first exposure to asbestos, recorded by ReNaM in the diagnosis period Variable Modality Adjusted mean latency by factors Diagnosis certainty Exposure modalities Significance in the linear generalised model MM certain MM probable 44.7 MM possible 45.9 Occupational 43.4 <0.001 Household 48.1 Environmental 48.0 Hobbies related 41.4 Morphology Epithelioid Biphasic 45.7 Fibrous 45.2 Not specified 44.6 Adjusted mean latency time (years) and statistical significance (p value) of each variable included in the multivariate generalised linear model. Model: latency = diagnosis certainty + exposure modalities + morphology + gender + anatomical site + age(covariate)* + year of diagnosis(covariate)*. * Statistical significance of covariates: p < are reported in Table 1. Mean latency was 44.6 years (CI 95% ), with a standard deviation of 12 years and a Gaussian distribution around the mean. The distribution of mean latency by anatomical site and gender is reported in Table 2. Among peritoneal MM female cases a mean latency of 36.8 years (CI 95% ) was estimated. As described above, the relationship between latency time and the explicative variables was analysed using a generalised linear regression model to adjust for possible confounding factors. As shown in Table 3, the latency period is not significantly related to morphology: differences among fibrous, epithelioid and biphasic cases are not relevant such as the level of diagnosis certainty. Latency length appeared related to the age at diagnosis, the year of diagnosis and the modalities of asbestos exposure. Latency increased constantly during the observed period with respect to the year of diagnosis (Fig. 1): estimated latency period among pleural MM cases diagnosed in 1993 and in 2001 was 41.7 and 46.2 years, respectively, and the increase during this period is close to a linear trend (p ANO- VA < 0.001; p ANOVA test for linear trend < 0.001). As expected, age at diagnosis is strongly related to latency length (p < by ANOVA) and this finding suggests conducting a multi-way analysis. In the multivariate model, mean latency (after age adjustment) among household (84 subjects) and environmentally exposed cases (98 subjects) was 48.1 and 48 years respectively and it was significantly longer than the latency of 43.4 years observed among the occupationally exposed ones (2342 subjects). Cases with a latency period shorter than 10 years are very rare (only four cases among the whole 2544). Mean latency time estimated among 20 cases with an exposure related to leisure activities (hydraulic and thermal areas, eternit handling) was significantly shorter (41.4). Concerning the economic sector of exposure for cases occupationally exposed, we observed a longer latency for workers of the shipbuilding and repair sector (46.3 years of latency after age-adjustment), a shorter latency in asbestos-cement industry (42.3) and latency almost equal to the general mean in the construction sector (43.7). 4. Discussion It is widely agreed that mesothelioma latency is very long (up to 40 years and more) and with a great range of variability, but analyses of case lists from large national population-based registers are not frequently reported. The discussion on mesothelioma latency is a relevant issue considering the still unclear process of cancer causation from asbestos fibre inhalation 13 and the lack of encouraging progress in mesothelioma treatments. 14 Moreover, any prediction about the future burden of mesothelioma incidence and mortality in both industrialised countries, most of which have banned asbestos use 9,15 20 and developing countries, where asbestos is currently used, 21 is related with latency time estimation. We have examined malignant mesothelioma latency over a large dataset produced from the national programme of malignant mesothelioma case collection, including all incident cases, in a diagnosis period of 9 years among a large part of Italian territory which included some areas with industrialised settlements and high incidence rates (in total, more than 240 million person/years of observations). Some preliminary issues regarding the characteristics of ReNaM dataset need to be discussed. We have considered eligible for the analysis about 50% of the whole case list collected (as described in the Methods section, questionnaires could not be administrated for 1621 MM recorded cases and, for 809 cases, questionnaires reported too poor information).

5 2726 EUROPEAN JOURNAL OF CANCER 43 (2007) latency period (mean and 95% CI; years) (n=77) 1994 (n=90) 1995 (n=190) 1996 (n=199) 1997 (n=191) 1998 (n=322) year of diagnosis 1999 (n=325) 2000 (n=530) 2001 (n=511) Fig. 1 Incident pleural malignant mesothelioma cases with available first exposure to asbestos, recorded by ReNaM in the diagnosis period Latency time (mean and 95% CI) by year of diagnosis. This could represent a selection bias. Moreover, in the not eligible group, the percentage of female cases (66.4% of 2629) is particularly high with respect to the analysed group (14.9% of 2544). The retrospective design of the study could miss the cases with shorter latency thereby overestimating the mean latent period. The investigation of asbestos exposure modalities in ReNaM are defined only by analysing structured questionnaires. Quantitative measures of exposure in the workplace are not available (it is almost impossible to plan a reconstruction of quantitative assessment of exposure after the asbestos ban in 1992). Moreover, estimated measures of asbestos fibres in the lung (as exposure marker) are very rare in Italy and not available at all in this study. It is not easy to precisely determine the onset of asbestos exposure. In the present study, the beginning of occupational asbestos exposure was defined as the year in which the subject began the first job considered as related to the exposure. This assumption is not completely suitable with working conditions in the period of extensive consumption of raw asbestos ( ). As a matter of fact, the beginning of a work period could not exactly correspond to the beginning of exposure to asbestos and it could lead to an overestimation of latency time. Cases of malignant mesothelioma reported in this study were collected in recent years; therefore, cases with relevant past exposures and short latency could be missing. From a methodological point of view it is necessary to underline that the limits of the observations in a population-based registry (i.e. the set registered cases since the beginning of registration limits at any point in time the upper range of dates of diagnosis that can be observed) combined with the fact that, in Italy, asbestos use declined and stopped in a well defined and limited calendar period, could be an estimated latency measure bias source. For MM cases of non occupational origin, the possible misclassification due to the beginning of the asbestos exposure period is an even more relevant issue. In these analyses, the first year of cohabitation (or the year of first exposure beginning for the cohabitant) was considered as the onset of exposure for cases with a household exposure and the residential history was used to define the onset of environmental exposure. In this latter case, the exposure onset was considered as the first year living near a potential environmental asbestos exposure source. The longer survival previously reported 11,22 and the shorter latency period for female peritoneal mesothelioma cases observed in this study, lead us to consider the possibility of a misclassification with female genital cancer. A variety of uncommon tumours of the peritoneum and of the ovary are closely related morphologically and histogenetically The possible diagnostic misclassification of female peritoneal mesothelioma 28,29 and the diagnostic utility of electron microscopy and immunohistochemistry as a gold standard in distinguishing between peritoneal mesothelioma and serous carcinoma, were recently underlined Taking into consideration the previous issues, the most relevant findings of this study are an observed increase in latency period in recent years, with a trend close to linear, and a shorter latency period observed among occupationally exposed subjects with respect to those environmentally and household exposed. Even before the Italian asbestos ban, measures to reduce exposure intensity were implemented in numerous workplaces, particularly in railway carriage construction plants, shipyards (construction area) and the asbestos-cement industry, where the use of sprayed crocidolite ceased during the 1970s. After that, during the 1980s, asbestos use ceased in most of the major textile plants as well as prevention measures being introduced in shipyards (maintenance area), in

6 EUROPEAN JOURNAL OF CANCER 43 (2007) the Military Navy and in the iron and steel industry, and even stricter security rules have been applied to the contract works of railway carriage decohibentation and maintenance of facilities for electricity production and distribution. The increase in latency time by year of diagnosis revealed in this study could be due to some reduction of the intensity of asbestos exposure in most workplaces during the period before the asbestos ban or to the increased proficiency of CORs to detect the earliest asbestos exposure. Our results provide some evidence of a relationship between exposure intensity and length of latency, despite the absence of individual quantitative exposure estimates. Latency for MM cases with environmental or household exposures was significantly longer than for work-related cases (48 and around 43 years respectively) and it is reasonable to assume that occupational exposures entail on average considerably higher fibre levels. The short latency period observed among cases whose exposure was due to asbestos use during leisure activities need to be deeply investigated, also considering the limited sample size (only 20 cases) and the not easily determined onset of asbestos exposure. It could be observed that these activities carried out at home are limited in duration in comparison with a standard 8 h work-shift, but are performed without effective protective measures, such as local exhausts and personal protection devices. The evaluation of the differences in mean latency period with respect to the specific job is a complex issue but some suggestions on the possible influence of exposure intensity on latency could stem. Limiting the analyses to few industries or occupations (those with at least 20 exposed cases), asbestos-cement workers in Italy have been exposed to fibre levels that, although poorly documented, were associated in some factories with a high risk of asbestos-related mortality 33 ; their latency was lower than the average for occupational cases. Furthermore, it is strongly reliable that the year of job beginning and the onset of asbestos exposure are very close in the asbestos-cement industry, suggesting that the latency period in this sector is a very consistent estimated measure. Despite the fact that occupation in the shipbuilding and repair industry has determined very high exposures in some jobs, and that it is associated with the highest mesothelioma incidence areas in Italy, latency in this sector appears longer than average. The longer latency for workers exposed in these activities had been previously described in Italy, and it can be explained when considering the occurrence of competing diseases (asbestos related lung cancer and asbestosis) in the group with most heavy exposure levels. 5 The absence of historical fibre concentration measurements in these activities in Italy, makes it very difficult to further investigate the possible relationship between exposure level and latency. Finally, the increasing trend in the latency length and the changes in the modalities of asbestos exposure during the period before the ban, induce expectations in the future of a MM case list affected, from an epidemiological point of view, by censored observations for competing causes of death. Conflict of interest statement None declared. Acknowledgement The authors thank Dr. Patrizia Scano for her support in linguistic revision of the text. REFERENCES 1. Burdorf A, Swuste P. An expert system for the evaluation of historical asbestos exposure as diagnostic criterion in asbestos-related diseases. Ann Occup Hyg 1999;43: Yeung P, Rogers A, Johnson A. Distribution of mesothelioma cases in different occupational groups and industries in Australia, Appl Occup Environ Hyg 1999;14(11): Burdorf A, Dahhan M, Swuste P. Occupational characteristics of cases with asbestos-related diseases in The Netherlands. Ann Occup Hyg 2003;47(6): Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med 1992;34: Bianchi C, Giarelli L, Grandi G, Brollo A, Ramani L, Zuch C. Latency periods in asbestos-related mesothelioma of the pleura. Eur J Cancer Prev 1997;6(2): Neumann V, Günther S, Müller KM, Fischer M. Malignant mesothelioma German mesothelioma register Int Arch Occup Environ Health 2001;74: Desoubeaux N, Bouvier V, Gervais R, et al. Malignant mesothelioma in Basse-Normandie, a French population study. Descriptive analysis, prognostic factors and survival. Rev Epidemiol Sante Publique 2001;49: Merler E, Lagazio C, Biggeri A. Trends in mortality from primary pleural tumor and incidence of pleural mesothelioma in Italy: a particularly serious situation. Epidemiol Prev 1999;23: Marinaccio A, Montanaro F, Mastrantonio M, et al. Predictions of mortality from pleural mesothelioma in Italy: a model based on asbestos consumption figures supports results from age-period-cohort models. Int J Cancer 2005;115: Nesti M, Marinaccio A, Chellini E. Malignant mesothelioma in Italy, Am J Ind Med 2004;45: Marinaccio A, Nesti M. Regional Operational Centers. Analysis of survival of mesothelioma cases in the Italian registry (ReNaM). Eur J Cancer 2003;39: Marinaccio A, Cauzillo G, Chellini E, et al. (Eds). Italian mesothelioma register Second report. ISPESL (Italian Insitute for Occupational Safety and Prevention), 2006, Rome (Italy). Available at Pott F, Roller M, Ziem U, et al. Carcinogenicity studies on natural and man-made fibres with the intraperitoneal test in rats. IARC Sci Publ 1989;90: Ismail-Khan R, Robinson LA, Williams Jr CC, Garrett CR, Bepler G, Simon GR. Malignant pleural mesothelioma: a comprehensive review. Cancer Control 2006;13: Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet 1995;345: Price B. Analysis of current trends in United States mesthelioma incidence. Am J Epidemiol 1997;145: Kjærgaard J, Andersson M. Incidence rates of malignant mesothelioma in Denmark and predicted future number of cases among men. Scand J Work Environ Health 2000;26: La Vecchia C, Decarli A, Peto J, Levi F, Tomei F, Negri A. An age, period and cohort analysis of pleural cancer mortality in Europe. Eur J Cancer Prev 2000;9:

7 2728 EUROPEAN JOURNAL OF CANCER 43 (2007) Banaei A, Auvert B, Goldberg M, Gueguen A, Luce D, Goldberg S. Future trends in mortality of French men from mesothelioma. Occup Environ Med 2000;57: Segura O, Burdorf A, Looman C. Update of predictions of mortality from pleural mesothelioma in the Netherlands. Occup Environ Med 2003;60: Kazan-Allen L. Asbestos and mesothelioma: worldwide trends. Lung Cancer 2005;49(Suppl 1):S Hoekstra AV, Riben MW, Frumovitz M, Liu J, Ramirez PT. Welldifferentiated papillary mesothelioma of the peritoneum: a pathological analysis and review of the literature. Gynecol Oncol 2005;98(1): Young RH, Clement PB. Malignant lesions of the female genital tract and peritoneum that may be underdiagnosed. Semin Diagn Pathol 1995;12: Attanoos RL, Webb R, Dojcinov SD, Gibbs AR. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Histopathology 2002;40(3): Davidson B, Risberg B, Berner A, Bedrossian CW, Reich R. The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma. Semin Diagn Pathos 2006;23(1): Davidson B, Zhang Z, Kleinberg L, et al. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin Cancer Res 2006;15(12): Sivertsen S, Berner A, Michael CW, Bedrossian C, Davidson B. Cadherin expression in ovarian carcinoma and malignant mesothelioma cell effusions. Acta Cytol 2006;50: Boffetta P. Epidemiology of peritoneal malignant mesothelioma a review. Ann Oncol 2007;18(6): Burdorf A, Jarvholm B, Siesling S. Asbestos exposure and differences in occurrence of peritoneal mesothelioma between men and women across countries. Occup Environ Med 2007; online June Ordonez NG. Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update. Adv Anat Pathol 2006;13(1): Ordonez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod Pathol 2006;19(1): Lloreta-Trull J. Extrathoracic mesothelial proliferations and their mimics. Ultrastruct Pathos 2006;30(1): Magnani C, Terracini B, Ivaldi C, Mancini A, Botta M. Tumor mortality and from other causes in asbestos cement workers at the Casale Montferrato plant. Med Lav 1996;87:

How To Calculate The Risk Of An Asbestos-Related Cancer

How To Calculate The Risk Of An Asbestos-Related Cancer European Journal of Cancer 39 (2003) 1290 1295 www.ejconline.com Analysis of survival of mesothelioma cases in the Italian register (ReNaM) A. Marinaccio a, *, M. Nesti a and Regional Operational Centers

More information

The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050

The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050 British Journal of Cancer (25) 92, 587 593 & 25 Cancer Research UK All rights reserved 7 92/5 $3. www.bjcancer.com The expected burden of mesothelioma mortality in Great Britain from 22 to 25 JT Hodgson*,1,

More information

EFFECT OF CHILDREN'S AGE AND LIFE EXPECTATION ON MESOTHELIOMA RISK 1

EFFECT OF CHILDREN'S AGE AND LIFE EXPECTATION ON MESOTHELIOMA RISK 1 EFFECT OF CHILDREN'S AGE AND LIFE EXPECTATION ON MESOTHELIOMA RISK 1 Robin Howie 2, Robin Howie Associates, Edinburgh It is generally accepted that the major risk from "low" level exposures to asbestos

More information

Emerging evidence that the ban on asbestos use is reducing the occurrence of pleural mesothelioma in Sweden

Emerging evidence that the ban on asbestos use is reducing the occurrence of pleural mesothelioma in Sweden 596500SJP0010.1177/1403494815596500B. Järvholm and A. BurdorfAsbestos ban reduces mesothelioma incidence research-article2015 Scandinavian Journal of Public Health, 1 7 Original Article Emerging evidence

More information

Occupational Characteristics of Cases with Asbestosrelated Diseases in The Netherlands

Occupational Characteristics of Cases with Asbestosrelated Diseases in The Netherlands Ann. occup. Hyg., Vol. 47, No. 6, pp. 485 492, 2003 2003 British Occupational Hygiene Society Published by Oxford University Press DOI: 10.1093/annhyg/meg062 Occupational Characteristics of Cases with

More information

Mesothelioma incidence in the neighbourhood of an asbestos-cement plant located in a national priority contaminated site

Mesothelioma incidence in the neighbourhood of an asbestos-cement plant located in a national priority contaminated site 322 Ann Ist Super Sanità 2014 Vol. 50, No. 4: 322-327 DOI: 10.4415/ANN_14_04_05 Mesothelioma incidence in the neighbourhood of an asbestos-cement plant located in a national priority contaminated site

More information

Mesothelioma incidence surveillance systems and claims for workers compensation. Epidemiological evidence and prospects for an integrated framework

Mesothelioma incidence surveillance systems and claims for workers compensation. Epidemiological evidence and prospects for an integrated framework Marinaccio et al. BMC Public Health 2012, 12:314 RESEARCH ARTICLE Open Access Mesothelioma incidence surveillance systems and claims for workers compensation. Epidemiological evidence and prospects for

More information

Table 2.4. Summary of design and findings from mesothelioma case-control studies

Table 2.4. Summary of design and findings from mesothelioma case-control studies categories Agudo et al. (2000) Barcelona and Cadiz, Spain 32 cases (77% males) of histologically con rmed malignant pleural mesothelioma identified from hospital in the region between //993 and 2/3/996.

More information

Mesothelioma among shipyard workers in Monfalcone, Italy

Mesothelioma among shipyard workers in Monfalcone, Italy Original Article Mesothelioma among shipyard workers in Monfalcone, Italy Abstract Background: The high mesothelioma incidence in Monfalcone, Italy, is mainly attributable to shipbuilding activity. Mesothelioma

More information

PATTERNS OF MORTALITY IN ASBESTOS FACTORY WORKERS IN LONDON*

PATTERNS OF MORTALITY IN ASBESTOS FACTORY WORKERS IN LONDON* PATTERNS OF MORTALITY IN ASBESTOS FACTORY WORKERS IN LONDON* M. L. Newhouse TUC Centenary Institute of Occupational Health London School of Hygiene and Tropical Medicine London WCIE 7HT. England G. Berry

More information

Lessons learned from the Western Australian experience with mesothelioma

Lessons learned from the Western Australian experience with mesothelioma Lessons learned from the Western Australian experience with mesothelioma Alison Reid, Western Australian Institute for Medical Research In partnership with Nick de Klerk, Nola Olsen, Jan Sleith, Geoffrey

More information

Survival of pleural malignant mesothelioma in Italy: A population-based study

Survival of pleural malignant mesothelioma in Italy: A population-based study Int. J. Cancer: 124, 201 207 (2009) ' 2008 Wiley-Liss, Inc. Survival of pleural malignant mesothelioma in Italy: A population-based study Fabio Montanaro 1, Rosalba Rosato 2, Manuela Gangemi 3, Sara Roberti

More information

IJC International Journal of Cancer

IJC International Journal of Cancer IJC International Journal of Cancer Pleural malignant mesothelioma epidemic: incidence, modalities of asbestos exposure and occupations involved from the Italian National Register Alessandro Marinaccio

More information

Cancer Mortality and Incidence of Mesothelioma in a Cohort of Wives of Asbestos Workers in Casale Monferrato, Italy

Cancer Mortality and Incidence of Mesothelioma in a Cohort of Wives of Asbestos Workers in Casale Monferrato, Italy Cancer Mortality and Incidence of Mesothelioma in a Cohort of Wives of Asbestos Workers in Casale Monferrato, Italy Daniela Ferrante, 1 Marinella Bertolotti, 1,2 Annalisa Todesco, 1 Dario Mirabelli, 2,3

More information

Changing Trends in Mesothelioma Incidence. Hans Weill, M.D. Professor of Medicine Emeritus Tulane University Medical Center

Changing Trends in Mesothelioma Incidence. Hans Weill, M.D. Professor of Medicine Emeritus Tulane University Medical Center Changing Trends in Mesothelioma Incidence Hans Weill, M.D. Professor of Medicine Emeritus Tulane University Medical Center International Conference on Chrysotile Montreal, May 23, 2006 Global Mesothelioma

More information

Mesothelioma National Register (Article 36, D.Lgs.n 277/91 Dpcm 308/02)

Mesothelioma National Register (Article 36, D.Lgs.n 277/91 Dpcm 308/02) ISPESL Italian National Institute for Occupational Safety and Prevention Occupational Medicine Department Epidemiology Unit Mesothelioma National Register (Article 36, D.Lgs.n 277/91 Dpcm 308/02) GUIDELINES

More information

NHS Barking and Dagenham Briefing on disease linked to Asbestos in Barking & Dagenham

NHS Barking and Dagenham Briefing on disease linked to Asbestos in Barking & Dagenham APPENDIX 1 NHS Barking and Dagenham Briefing on disease linked to Asbestos in Barking & Dagenham 1. Background 1.1. Asbestos Asbestos is a general name given to several naturally occurring fibrous minerals

More information

PROTOCOL OF THE RITA DATA QUALITY STUDY

PROTOCOL OF THE RITA DATA QUALITY STUDY PROTOCOL OF THE RITA DATA QUALITY STUDY INTRODUCTION The RITA project is aimed at estimating the burden of rare malignant tumours in Italy using the population based cancer registries (CRs) data. One of

More information

Asbestos-Related Cancer Research and Prevention

Asbestos-Related Cancer Research and Prevention Asbestos-Related Cancer Research and Prevention Professor Nico van Zandwijk Asbestos Diseases Research Institute University of Sydney International Conference on Asbestos Awareness and Management 18 November

More information

BY THE NUMBERS: THE FUTURE OF MESOTHELIOMA IN AMERICA

BY THE NUMBERS: THE FUTURE OF MESOTHELIOMA IN AMERICA BY THE NUMBERS: THE FUTURE OF MESOTHELIOMA IN AMERICA 1 CUTTING-EDGE ISSUES IN ASBESTOS LITIGATION CONFERENCE Scott Masterson Lewis, Brisbois, Bisgaard & Smith, LLP 1180 Peachtree Street, NE, Suite 2900

More information

The Trend in Airborne Asbestos Concentrations at Plants Manufacturing Asbestos-Containing Products in Japan

The Trend in Airborne Asbestos Concentrations at Plants Manufacturing Asbestos-Containing Products in Japan Industrial Health 2001, 39, 127 131 Original Article The Trend in Airborne Asbestos Concentrations at Plants Manufacturing Asbestos-Containing Products in Japan Koji YOSHIZUMI 1 *, Hajime HORI 2, Toshihiko

More information

Rare Thoracic Tumours

Rare Thoracic Tumours Rare Thoracic Tumours 1. Epithelial Tumour of Trachea 1 1.1 General Results Table 1. Epithelial Tumours of Trachea: Incidence, Trends, Survival Flemish Region 2001-2010 Both Sexes Incidence Trend EAPC

More information

Mortality Experience in an Historical Cohort of Chrysotile Asbestos Textile Workers

Mortality Experience in an Historical Cohort of Chrysotile Asbestos Textile Workers Table of Contents WS-E-03 Carlo Mamo Mortality Experience in an Historical Cohort of Chrysotile Asbestos Textile Workers Carlo Mamo 1, Giuseppe Costa 2 1 Epidemiology Unit, Piedmont Region, Grugliasco,

More information

Estimation of Future Mortality From Pleural Malignant Mesothelioma in Japan Based on an Age-Cohort Model

Estimation of Future Mortality From Pleural Malignant Mesothelioma in Japan Based on an Age-Cohort Model AMERICAN JOURNAL OF INDUSTRIAL MEDICINE 49:1 7 (26) Estimation of Future Mortality From Pleural Malignant Mesothelioma in Japan Based on an Age-Cohort Model Takehiko Murayama, PhD, 1 Ken Takahashi, MD,

More information

Update of the scientific evidence on asbestos and cancer. Kurt Straif, MD MPH PhD. The IARC Monographs

Update of the scientific evidence on asbestos and cancer. Kurt Straif, MD MPH PhD. The IARC Monographs Update of the scientific evidence on asbestos and cancer Kurt Straif, MD MPH PhD International Agency for Research on Cancer Lyon, France World Health Organisation Asturias, 17 March 2011 The IARC Monographs

More information

How To Determine The Risk Of Mesothelioma In Brake Workers

How To Determine The Risk Of Mesothelioma In Brake Workers 1 Risk Anal. 2004 Jun;24(3):547-52. Related Articles, Links Mesothelioma among brake mechanics: an expanded analysis of a casecontrol study. Hessel PA, Teta MJ, Goodman M, Lau E. Exponent, Wood Dale, IL

More information

Actuarial projections for mesothelioma: an epidemiological perspective Mark Clements, Geoffrey Berry and Jill Shi

Actuarial projections for mesothelioma: an epidemiological perspective Mark Clements, Geoffrey Berry and Jill Shi Actuarial projections for mesothelioma: an epidemiological perspective Mark Clements, Geoffrey Berry and Jill Shi 27 slides to go Who are we? I am an epidemiologist/biostatistician from the Australian

More information

Asbestos related cancers

Asbestos related cancers New cancer cases 1954-215 in Finland, Men Pukkala et al. 26 Asbestos related cancers Panu Oksa, MD, docent Course on asbestos-related diseases Tartu 4-5.12.26 Asbestos related cancer / FIOH / PO / 1.1.27

More information

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are

More information

Int. J. Cancer: 115, 142 147 (2005) 2005 Wiley-Liss, Inc.

Int. J. Cancer: 115, 142 147 (2005) 2005 Wiley-Liss, Inc. Int. J. Cancer: 115, 142 147 (2005) 2005 Wiley-Liss, Inc. Predictions of mortality from pleural mesothelioma in Italy: a model based on asbestos consumption figures supports results from age-period-cohort

More information

Survey of Mesothelioma Associated with Asbestos Exposure in Japan

Survey of Mesothelioma Associated with Asbestos Exposure in Japan The research and development and the dissemination projects related to the 13 fields of occupational injuries and illnesses Survey of Mesothelioma Associated with Asbestos Exposure in Japan Clinical characteristics

More information

Survey on the Mortality from Malignant Tumors of Female Asbestos Spinning Workers

Survey on the Mortality from Malignant Tumors of Female Asbestos Spinning Workers Table of Contents WS-E-12 Xing Zhang Survey on the Mortality from Malignant Tumors of Female Asbestos Spinning Workers Xing Zhang 1, Tong-da Sun 2, Nan-feng Shi 2, Li-qiu Zhu 1, Kenji Morinaga 3 1 Institute

More information

Carcinogens in the Construction Industry

Carcinogens in the Construction Industry Carcinogens in the Construction Industry BENGT JÄRVHOLM Department of Public Health and Clinical Medicine, Umeå University, SE-901 85 Umeå, Sweden ABSTRACT: The construction industry is a complex work

More information

Effects of combined therapies on the survival of pleural mesothelioma patients treated in Brescia, 1982-2006

Effects of combined therapies on the survival of pleural mesothelioma patients treated in Brescia, 1982-2006 Tu mo ri, 98: 215-219, 2012 Effects of combined therapies on the survival of pleural mesothelioma patients treated in Brescia, 1982-2006 Pietro Gino Barbieri 1, Alessandro Marinaccio 2, Pierpaolo Ferrante

More information

The epidemiology and treatment of mesothelioma in South East England 1985 2002

The epidemiology and treatment of mesothelioma in South East England 1985 2002 The epidemiology and treatment of mesothelioma in South East England 1985 2002 V Mak, E Davies, V Putcha, B Choodari-Oskooei, H Møller King s College London, Thames Cancer Registry, London, UK Correspondence

More information

Mesothelioma Incidence and Community Asbestos Exposure

Mesothelioma Incidence and Community Asbestos Exposure ENVIRONMENTAL RESEARCH 75, 34 40 (1997) ARTICLE NO. ER973770 Mesothelioma Incidence and Community Asbestos Exposure Michael Berry Consumer and Environmental Health Services, New Jersey Department of Health

More information

Scientific Update on Safe Use of Asbestos. Robert P. Nolan, PhD International Environmental Research Foundation New York, New York www.ierfinc.

Scientific Update on Safe Use of Asbestos. Robert P. Nolan, PhD International Environmental Research Foundation New York, New York www.ierfinc. Scientific Update on Safe Use of Asbestos Robert P. Nolan, PhD International Environmental Research Foundation New York, New York www.ierfinc.org When We Talk about Asbestos What Do We Mean? Anthophyllite

More information

MESOTHELIOMA IN AUSTRALIA INCIDENCE 1982 TO 2008 MORTALITY 1997 TO 2007

MESOTHELIOMA IN AUSTRALIA INCIDENCE 1982 TO 2008 MORTALITY 1997 TO 2007 MESOTHELIOMA IN AUSTRALIA INCIDENCE 1982 TO 28 MORTALITY 1997 TO 27 August 212 Safe Work Australia Mesothelioma in Australia Incidence 1982 to 28 Deaths 1997 to 27 August 212 Acknowledgement Data on the

More information

Mesothelioma in Australia: Incidence (1982 to 2013) and Mortality (1997 to 2012)

Mesothelioma in Australia: Incidence (1982 to 2013) and Mortality (1997 to 2012) Mesothelioma in Australia: Incidence (1982 to 213) and Mortality (1997 to 212) 215 Disclaimer The information provided in this document can only assist you in the most general way. This document does not

More information

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY MALIGNANT MESOTHELIOMA CLASSIFICATION MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo,

More information

Health effects of occupational exposure to asbestos dust

Health effects of occupational exposure to asbestos dust Health effects of occupational exposure to asbestos dust Authors: N.Szeszenia-Dąbrowska, U.Wilczyńska The major health effects of workers' exposure to asbestos dust include asbestosis, lung cancer and

More information

Asbestos Health Risks. Dr Andrew Pengilley Acting Chief Health Officer

Asbestos Health Risks. Dr Andrew Pengilley Acting Chief Health Officer Asbestos Health Risks Dr Andrew Pengilley Acting Chief Health Officer Asbestos Asbestos is a name given to several different fibrous minerals Three main commercial types are Chrysotile (white asbestos)

More information

How To Prevent Asbestos Related Diseases

How To Prevent Asbestos Related Diseases BD5.3 Report of Working Groups Elimination of Asbestos-related Diseases ICOH 2012 March 18, 2012 Cancun Report of WG Elimination of Asbestos-related Diseases Dr. Sherson mail to ICOH President of 7 December

More information

Malignant Mesothelioma in Australia, 1945 2000

Malignant Mesothelioma in Australia, 1945 2000 Ann. occup. Hyg., Vol. 46, Supplement 1, pp. 160 165, 2002 2002 British Occupational Hygiene Society Published by Oxford University Press DOI: 10.1093/annhyg/mef669 Malignant Mesothelioma in Australia,

More information

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo, Finland 2nd Nordic Conference on Applied

More information

Pietro Comba, Amerigo Zona Dipartimento di Ambiente e Connessa Prevenzione Primaria. Istituto Superiore di Sanità, Roma

Pietro Comba, Amerigo Zona Dipartimento di Ambiente e Connessa Prevenzione Primaria. Istituto Superiore di Sanità, Roma ASBESTOS-RELATED DISEASES Pietro Comba, Amerigo Zona Dipartimento di Ambiente e Connessa Prevenzione Primaria. Istituto Superiore di Sanità, Roma Asbestos-related diseases include asbestosis, pleural plaques,

More information

Health Effects of Asbestos Exposure

Health Effects of Asbestos Exposure Health Effects of Asbestos Exposure Jill Dyken, PhD, PE John Wheeler, PhD, DABT Agency for Toxic Substances and Disease Registry Asbestos Science Seminar Folsom, California August 18-19, 2004 Agency for

More information

Industrial Injuries Advisory Council Information Note CANCERS OF THE LARYNX OR OVARY AND WORK WITH ASBESTOS. February 2015

Industrial Injuries Advisory Council Information Note CANCERS OF THE LARYNX OR OVARY AND WORK WITH ASBESTOS. February 2015 Industrial Injuries Advisory Council Information Note CANCERS OF THE LARYNX OR OVARY AND WORK WITH ASBESTOS February 2015 Background 1. Following a request from the Asbestos Victims Support Groups Forum,

More information

Malignant Mesothelioma Mortality --- United States, 1999--2005

Malignant Mesothelioma Mortality --- United States, 1999--2005 Weekly April 24, 2009 / 58(15);393-396 Malignant Mesothelioma Mortality --- United States, 1999--2005 Malignant mesothelioma is a fatal cancer primarily associated with exposure to asbestos. The latency

More information

MESOTHELIOMA IN AUSTRALIA INCIDENCE 1982 TO 2009 MORTALITY 1997 TO 2011

MESOTHELIOMA IN AUSTRALIA INCIDENCE 1982 TO 2009 MORTALITY 1997 TO 2011 MESOTHELIOMA IN AUSTRALIA INCIDENCE 1982 TO 29 MORTALITY 1997 TO 211 OCTOBER 213 Safe Work Australia Mesothelioma in Australia Incidence 1982 to 29 Mortality 1997 to 211 OCTOBER 213 Acknowledgement Disclaimer

More information

National Institute of Occupational Safety and Prevention. Occupational Health Department

National Institute of Occupational Safety and Prevention. Occupational Health Department National Institute of Occupational Safety and Prevention Occupational Health Department LABORATORY OF OCCUPATIONAL EPIDEMIOLOGY AND HEALTH STATISTICS THE NATIONAL MESOTHELIOMA REGISTRY (ReNaM) (art. 36

More information

Compensation for Environmental and Domestic Exposure Cases

Compensation for Environmental and Domestic Exposure Cases Table of Contents PL-5-01 Bob Ruers Compensation for Environmental and Domestic Exposure Cases Bob Ruers Former Dutch Senator, founding member of Dutch Asbestos Committee and Solicitor, the Netherlands

More information

Mesothelioma Trends as Predictors of the Asbestos- Related Lung Cancer Burden

Mesothelioma Trends as Predictors of the Asbestos- Related Lung Cancer Burden Mesothelioma Trends as Predictors of the Asbestos- Related Lung Cancer Burden Valerie McCormack UICC World Cancer Congress Montreal August 2012 Outline Background Estimating the lung cancer mortality burden

More information

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,

More information

Asbestos related health risks

Asbestos related health risks Asbestos related health risks Pascal DUMORTIER *,** & Paul DE VUYST** *a-ulab ** Chest Department Hopital ERASME Asbestos related health risks Asbestos : some facts Asbestos related diseases Detection

More information

Summary of treatment benefits

Summary of treatment benefits Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell

More information

Mesothelioma mortality in Great Britain 1968-2009. Summary 2. Overall scale of disease including trends 3. Region 6. Occupation 7

Mesothelioma mortality in Great Britain 1968-2009. Summary 2. Overall scale of disease including trends 3. Region 6. Occupation 7 Health and Safety Executive Mesothelioma Mesothelioma mortality in Great Britain 1968-2009 Contents Summary 2 Overall scale of disease including trends 3 Region 6 Occupation 7 Estimation of the future

More information

Lung cancer and asbestos

Lung cancer and asbestos Lung cancer and asbestos Bureau Veritas Training Bill Sanderson For the benefit of business and people To begin with.. There are known knowns, that is there are things we know that we know. There are known

More information

Asbestos: health effects and risk. Peter Franklin Senior Scientific Officer, EHD Senior Research Fellow, UWA

Asbestos: health effects and risk. Peter Franklin Senior Scientific Officer, EHD Senior Research Fellow, UWA Asbestos: health effects and risk Peter Franklin Senior Scientific Officer, EHD Senior Research Fellow, UWA What is asbestos Naturally occurring mineral that has crystallised to form long thin fibres and

More information

Occupational respiratory diseases due to Asbestos. Dirk Dahmann, IGF, Bochum

Occupational respiratory diseases due to Asbestos. Dirk Dahmann, IGF, Bochum Occupational respiratory diseases due to Asbestos Dirk Dahmann, IGF, Bochum Contents Introduction Diseases Further Effects Preventive Strategies Conclusion Asbestos minerals Woitowitz, 2003 Imports (+

More information

THE AUSTRALIAN MESOTHELIOMA REGISTRY (AMR)

THE AUSTRALIAN MESOTHELIOMA REGISTRY (AMR) THE AUSTRALIAN MESOTHELIOMA REGISTRY (AMR) Professor Nico van Zandwijk Director Asbestos Diseases Research Institute US US UK UK COUNTRY NZ CAN COUNTRY NZ CAN AUS AUS Mesothelioma International context

More information

Asbestos and Mesothelioma a briefing document for the Metropolitan Police

Asbestos and Mesothelioma a briefing document for the Metropolitan Police Asbestos and Mesothelioma a briefing document for the Metropolitan Police Prepared by Professor John Cherrie, Heriot Watt University, Edinburgh, UK. Introduction The purpose of this document is to provide

More information

ASBESTOS DISEASES. Dr Alastair Robertson

ASBESTOS DISEASES. Dr Alastair Robertson ASBESTOS DISEASES Dr Alastair Robertson Occupational Health Department University Hospital Birmingham Birmingham B29 6JF 01216278285 Alastair.robertson@uhb.nhs.uk Occupational Lung Disease Unit Birmingham

More information

Case of the. Month October, 2012

Case of the. Month October, 2012 Case of the Month October, 2012 Case The patient is a 47-year-old male with a 3-week history of abdominal pain. A CT scan of the abdomen revealed a suggestion of wall thickening at the tip of the appendix

More information

Assessment of cancer risks due to environmental exposure to asbestos

Assessment of cancer risks due to environmental exposure to asbestos Journal of Exposure Science and Environmental Epidemiology (2010) 20, 478 485 r 2010 Nature America, Inc. All rights reserved 1559-0631/10 www.nature.com/jes Assessment of cancer risks due to environmental

More information

Review of Eliminating occupational cancer in Europe and globally by J. Takala

Review of Eliminating occupational cancer in Europe and globally by J. Takala Review of Eliminating occupational cancer in Europe and globally by J. Takala There primary concerns of this manuscript are outlined below. More detail discussion of these points is presented on the following

More information

Asbestos Exposure and Survival in Malignant Mesothelioma: A Description of 122 Consecutive Cases at an Occupational Clinic

Asbestos Exposure and Survival in Malignant Mesothelioma: A Description of 122 Consecutive Cases at an Occupational Clinic Original Article 1 Danish Ramazzini Center, Department of Occupational Medicine, Aalborg Hospital, Aarhus University hospital, Aalborg, Denmark 2 Department of Infectious Diseases, Rigshospitalet, Copenhagen,

More information

Asbestos and Mesothelioma in Thailand

Asbestos and Mesothelioma in Thailand MD, DScMed, FRCP, FRACP, hon. FACP Emeritus Professor and Fellow of the Academy of Science, the Royal Institute of Thailand Abstract Chrysotile, a serpentile asbestos, has been used in a number of Thai

More information

J of Evidence Based Med & Hlthcare, pissn- 2349-2562, eissn- 2349-2570/ Vol. 2/Issue 33/Aug. 17, 2015 Page 5063

J of Evidence Based Med & Hlthcare, pissn- 2349-2562, eissn- 2349-2570/ Vol. 2/Issue 33/Aug. 17, 2015 Page 5063 PERITONEAL MALIGNANT MESOTHELIOMA: A RARE S. R. Dhamotharan 1, S. Shanthi Nirmala 2, F. Celine Foustina Mary 3, M. Arul Raj Kumar 4, R. Vinothprabhu 5 HOW TO CITE THIS ARTICLE: S. R. Dhamotharan, S. Shanthi

More information

Malignant Mesothelioma Among Employees of a Connecticut Factory that Manufactured Friction Materials Using Chrysotile Asbestos

Malignant Mesothelioma Among Employees of a Connecticut Factory that Manufactured Friction Materials Using Chrysotile Asbestos Ann. Occup. Hyg., Vol. 54, No. 6, pp. 692 696, 2010 Ó The Author 2010. Published by Oxford University Press on behalf of the British Occupational Hygiene Society doi:10.1093/annhyg/meq046 Malignant Mesothelioma

More information

Varianti genetiche e interazione gene-asbesto nel mesotelioma pleurico

Varianti genetiche e interazione gene-asbesto nel mesotelioma pleurico Varianti genetiche e interazione gene-asbesto nel mesotelioma pleurico Tunesi Sara, Ferrante Daniela, Mirabelli Dario, Andorno Silvano, Betti Marta, Fiorito Giovanni, Guarrera Simonetta, Casalone Elisabetta,

More information

Malignant Mesothelioma: an Update

Malignant Mesothelioma: an Update Malignant Mesothelioma: an Update Nico van Zandwijk Asbestos Diseases Research Institute Bernie Banton Centre University of Sydney Australia Physicians Week RACP 19-5-2009 Health Risks of Asbestos Fibers

More information

Mesothelioma: Questions and Answers

Mesothelioma: Questions and Answers CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Mesothelioma: Questions

More information

australian mesothelioma registry

australian mesothelioma registry australian mesothelioma registry 1st Annual Report Mesothelioma in Australia 2011 The Australian Mesothelioma Registry is funded by Safe Work Australia and Comcare. Creative Commons ISBN 978-0-642-78563-3

More information

Future Trends of Mesothelioma Mortality in Japan Based on a Risk Function

Future Trends of Mesothelioma Mortality in Japan Based on a Risk Function Industrial Health 2012, 50, 197 204 Original Article Future Trends of Mesothelioma Mortality in Japan Based on a Risk Function Tomoya MYOJIN 1, Kenichi AZUMA 2 *, Jiro OKUMURA 2 and Iwao UCHIYAMA 3 1 Department

More information

MORTALITY STUDY OF WORKERS COMPENSATED FOR ASBESTOSIS IN POLAND, 1970 1997

MORTALITY STUDY OF WORKERS COMPENSATED FOR ASBESTOSIS IN POLAND, 1970 1997 International Journal of Occupational edicine and Environmental Health, Vol. 15, No. 3, 267 278, 2002 ORTALITY STUDY O WORKERS COPENSATED OR ASBESTOSIS IN POLAND, 1970 1997 NEONILA SZESZENIA-DĄBROWSKA,

More information

Population-based survival for malignant mesothelioma after introduction of novel chemotherapy

Population-based survival for malignant mesothelioma after introduction of novel chemotherapy Eur Respir J 2012; 40: 185 189 DOI: 10.1183/09031936.00153611 CopyrightßERS 2012 Population-based survival for malignant mesothelioma after introduction of novel chemotherapy Ronald A.M. Damhuis*, Caroline

More information

Update on Mesothelioma

Update on Mesothelioma November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical

More information

Influence of Fiber Type, Size, and Number in Human Disease: Conclusions from Fiber Burden Analysis

Influence of Fiber Type, Size, and Number in Human Disease: Conclusions from Fiber Burden Analysis Influence of Fiber Type, Size, and Number in Human Disease: Conclusions from Fiber Burden Analysis Andrew Churg, MD Department of Pathology University of British Columbia Vancouver, BC, Canada Techniques,

More information

A Cross-Sectional Study of Asbestos- Related Morbidity and Mortality in Vermonters Residing Near an Asbestos Mine November 3, 2008

A Cross-Sectional Study of Asbestos- Related Morbidity and Mortality in Vermonters Residing Near an Asbestos Mine November 3, 2008 A Cross-Sectional Study of Asbestos- Related Morbidity and Mortality in Vermonters Residing Near an Asbestos Mine 108 Cherry Street, PO Box 70 Burlington, VT 05402 802.863.7200 healthvermont.gov A Cross-Sectional

More information

Singapore Cancer Registry Annual Registry Report Trends in Cancer Incidence in Singapore 2009 2013. National Registry of Diseases Office (NRDO)

Singapore Cancer Registry Annual Registry Report Trends in Cancer Incidence in Singapore 2009 2013. National Registry of Diseases Office (NRDO) Singapore Cancer Registry Annual Registry Report Trends in Cancer Incidence in Singapore 2009 2013 National Registry of Diseases Office (NRDO) Released November 3, 2014 Acknowledgement This report was

More information

chapter 5. Quality control at the population-based cancer registry

chapter 5. Quality control at the population-based cancer registry chapter 5. Quality control at the population-based cancer registry All cancer registries should be able to give some objective indication of the quality of the data that they have collected. The methods

More information

HEALTH CARE FOR EXPOSURE TO ASBESTOS. 2010 The SafetyNet Centre for Occupational Health and Safety Research Memorial University www.safetynet.mun.

HEALTH CARE FOR EXPOSURE TO ASBESTOS. 2010 The SafetyNet Centre for Occupational Health and Safety Research Memorial University www.safetynet.mun. HEALTH CARE FOR PATIENTS WITH EXPOSURE TO ASBESTOS 2010 The SafetyNet Centre for Occupational Health and Safety Research Memorial University www.safetynet.mun.ca HEALTH CARE FOR PATIENTS WITH EXPOSURE

More information

Call for an International Ban on Asbestos

Call for an International Ban on Asbestos Call for an International Ban on Asbestos To eliminate the burden of disease and death that is caused worldwide by exposure to asbestos, The Collegium Ramazzini calls for an immediate ban on all mining

More information

Mortality of workers in a French asbestos cement factory 1940-82

Mortality of workers in a French asbestos cement factory 1940-82 British Journal of Industrial Medicine 1985;42: 219-225 Mortality of workers in a French asbestos cement factory 1940-82 A M ALIES-PATIN AND A J VALLERON Unite de Recherches Biomathematiques et Biostatistiques,

More information

Epidemiological patterns of asbestos exposure and spatial clusters of incident cases of malignant mesothelioma from the Italian national registry

Epidemiological patterns of asbestos exposure and spatial clusters of incident cases of malignant mesothelioma from the Italian national registry Corfiati et al. BMC Cancer (2015) 15:286 DOI 10.1186/s12885-015-1301-2 RESEARCH ARTICLE Open Access Epidemiological patterns of asbestos exposure and spatial clusters of incident cases of malignant mesothelioma

More information

NISG Asbestos. Caroline Kirton

NISG Asbestos. Caroline Kirton NISG Asbestos Caroline Kirton 1 The Control of Asbestos Regulations 2012, Regulation 10 requires every employer to ensure that adequate information, instruction and training is given to their employees

More information

Worldwide mesothelioma mortality trends

Worldwide mesothelioma mortality trends Worldwide mesothelioma mortality trends Harvard Symposium 24 th July 2009 Julian Peto London School of Hygiene and Tropical Medicine and Institute of Cancer Research Asbestos-related diseases Asbestosis

More information

Case Report Pleural Mesothelioma Presenting as Periumbilical Metastasis: The First Clinical Documentation

Case Report Pleural Mesothelioma Presenting as Periumbilical Metastasis: The First Clinical Documentation Volume 2013, Article ID 198729, 4 pages http://dx.doi.org/10.1155/2013/198729 Case Report Pleural Mesothelioma Presenting as Periumbilical Metastasis: The First Clinical Documentation R. F. Falkenstern-Ge,

More information

ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3

ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3 ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3 HOW TO CITE THIS ARTICLE: Gorantla Sambasivarao, Namballa Usharani,

More information

Asbestos Disease: An Overview for Clinicians Asbestos Exposure

Asbestos Disease: An Overview for Clinicians Asbestos Exposure Asbestos Asbestos Disease: An Overview for Clinicians Asbestos Exposure Asbestos: A health hazard Exposure to asbestos was a major occupational health hazard in the United States. The first large-scale

More information

Asbestos Related Diseases

Asbestos Related Diseases Asbestos Related Diseases Asbestosis Mesothelioma Lung Cancer Pleural Disease Asbestosis and Mesothelioma (LUNG CANCER) Support Group 1800 017 758 www.amsg.com.au ii Helping you and your family through

More information

Estimating the Global Burden of Asbestos-related Diseases Using YPLL

Estimating the Global Burden of Asbestos-related Diseases Using YPLL Ramazzini Days Carpi, Italy October, 2012 Estimating the Global Burden of Asbestos-related Diseases Using YPLL Ken Takahashi 1, Ying Jiang 1, Mehrnoosh Movahed 1, Giang Vinh Le 2,1, Eun-Kee Park 3,1, Rokho

More information

Mesothelioma risk after 40 years since first exposure to asbestos: a pooled analysis

Mesothelioma risk after 40 years since first exposure to asbestos: a pooled analysis Downloaded from thorax.bmj.com on June 5, 2014 - Published by group.bmj.com Thorax Online First, published on May 19, 2014 as 10.1136/thoraxjnl-2013-204161 Respiratory epidemiology ORIGINAL ARTICLE Mesothelioma

More information

Mesothelioma in Northeastern Minnesota and Two Occupational Cohorts: 2007 Update. December 7, 2007

Mesothelioma in Northeastern Minnesota and Two Occupational Cohorts: 2007 Update. December 7, 2007 Mesothelioma in Northeastern Minnesota and Two Occupational Cohorts: 2007 Update December 7, 2007 Center for Occupational Health and Safety Chronic Disease and Environmental Epidemiology Section Minnesota

More information

Mesothelioma in Northeastern Minnesota and Two Occupational Cohorts: 2007 Update. December 7, 2007

Mesothelioma in Northeastern Minnesota and Two Occupational Cohorts: 2007 Update. December 7, 2007 Mesothelioma in Northeastern Minnesota and Two Occupational Cohorts: 2007 Update December 7, 2007 Center for Occupational Health and Safety Chronic Disease and Environmental Epidemiology Section Minnesota

More information

Global mesothelioma deaths reported to the World. Health Organization between 1994 and 2008

Global mesothelioma deaths reported to the World. Health Organization between 1994 and 2008 This online first version has been peer-reviewed, accepted and edited, but not formatted and finalized with corrections from authors and proofreaders. Global mesothelioma deaths reported to the World Health

More information

Asbestos Related Diseases. Asbestosis Mesothelioma Lung Cancer Pleural Disease. connecting raising awareness supporting advocating

Asbestos Related Diseases. Asbestosis Mesothelioma Lung Cancer Pleural Disease. connecting raising awareness supporting advocating Asbestos Related Diseases Asbestosis Mesothelioma Lung Cancer Pleural Disease connecting raising awareness supporting advocating 1800 017 758 www.asbestosassociation.com.au Asbestos lagging was widely

More information

Sir William Osler: Listen to the patient; the patient tells you everything.

Sir William Osler: Listen to the patient; the patient tells you everything. Sir William Osler: Listen to the patient; the patient tells you everything. Jean-Martin Charcot: The patient is a liar. Epidemiology of Mesothelioma Jeffrey H. Mandel, MD, MPH Division of Environmental

More information

ANNEX 2: Assessment of the 7 points agreed by WATCH as meriting attention (cover paper, paragraph 9, bullet points) by Andy Darnton, HSE

ANNEX 2: Assessment of the 7 points agreed by WATCH as meriting attention (cover paper, paragraph 9, bullet points) by Andy Darnton, HSE ANNEX 2: Assessment of the 7 points agreed by WATCH as meriting attention (cover paper, paragraph 9, bullet points) by Andy Darnton, HSE The 7 issues to be addressed outlined in paragraph 9 of the cover

More information